Description
Infliximab ELISA Kit
The Infliximab ELISA Kit (SKU: GXEL00039) is a high-sensitivity quantitative ELISA assay developed for the quantitative measurement of Infliximab in Plasma, Serum. The assay delivers a detection range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml and is read colorimetrically at 450 nm, making it well suited to quantitative research workflows.
Infliximab is a chimeric monoclonal antibody and used to treat auto- immune disorders. Infliximab reduces the amount of active human tumour necrosis factor alpha (hTNFa) in the body by binding to it and preventing it from signaling the receptors for TNFa on the surface of various cell types. TNFa is one of the key cytokines that triggers and sustains the inflammatory reactions. Infliximab is used for the treatment of psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis.
Supplied with pre-coated microplates and all core reagents, the Infliximab ELISA Kit gives you a validated, ready-to-use solution for Infliximab research. Get accurate and reliable results with the Infliximab ELISA Kit from Assay Genie.
| Product Name: | Infliximab ELISA Kit |
| SKU: | GXEL00039 |
| Accession: | P01375 |
| Alternative Names: | TA-650, cA2, 170277-31-3 |
| Assay Type: | Quantitative |
| Detection Method: | Colorimetric |
| Sensitivity: | 0.156 μg/ml |
| Range: | 0.31-5 μg/mL |
| Sample Type: | Plasma, Serum |
| Storage: | 2-8°C. See Storage & Stability for details. |
| Note: | For Research Use Only. Not for diagnostic procedures. |
| Parameter | Specification |
|---|---|
| Assay Type | Quantitative |
| Detection Method | Colorimetric |
| Sensitivity | 0.156 μg/ml |
| Detection Range | 0.31-5 μg/mL |
| Recovery | 80-120% |
| Sample Types | Plasma, Serum |
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Store the kit at 2-8°C on receipt. Avoid repeated freeze-thaw cycles.
